The Global Alliance for TB Drug Development has granted Drugs for Neglected Diseases Initiative rights to develop a class of potential anti-TB compound offering hope of treating Chagas disease, African sleeping sickness and leishmaniasis.
The agreement is between two not-for-profit drug developers and will speed progress toward markedly improved therapy of variety neglected diseases.
The announcement was made in New York and Geneva, Switzerland, last Wednesday.
The TB Alliance is a not-for-profit product development partnership searching for better and faster cures for TB. Drugs for Neglected Diseases Initiative is a nonprofit product development partnership working to research and develop new treatments for other neglected diseases, in particular human African trypanosomiasis.
The agreement highlights the efficiency and synergy of product development partnerships and how investment in them is producing a robust and diverse pipeline of tools to treat neglected diseases.
"Developing drugs to fight neglected diseases is about restoring to the world's poor one of the most fundamental human rights - their health," said TB Alliance CEO Mel Spigelmane.
Under the agreement, the TB Alliance grants Drugs for Neglected Diseases Initiative rights to develop a series of compounds from the nitroimidazole class for use against many neglected tropical diseases.
Pact to fight diseases
The Global Alliance for TB Drug Development has granted Drugs for Neglected Diseases Initiative rights to develop a class of potential anti-TB compound offering hope of treating Chagas disease, African sleeping sickness and leishmaniasis.
The agreement is between two not-for-profit drug developers and will speed progress toward markedly improved therapy of variety neglected diseases.
The announcement was made in New York and Geneva, Switzerland, last Wednesday.
The TB Alliance is a not-for-profit product development partnership searching for better and faster cures for TB. Drugs for Neglected Diseases Initiative is a nonprofit product development partnership working to research and develop new treatments for other neglected diseases, in particular human African trypanosomiasis.
The agreement highlights the efficiency and synergy of product development partnerships and how investment in them is producing a robust and diverse pipeline of tools to treat neglected diseases.
"Developing drugs to fight neglected diseases is about restoring to the world's poor one of the most fundamental human rights - their health," said TB Alliance CEO Mel Spigelmane.
Under the agreement, the TB Alliance grants Drugs for Neglected Diseases Initiative rights to develop a series of compounds from the nitroimidazole class for use against many neglected tropical diseases.